Ovarian cancer is the leading cause of morbidity/mortality from gynecologic malignancy. Early detection of disease is difficult due to the propensity for ovarian cancer to disseminate throughout the peritoneum. Currently, there is no single accurate test to detect primary or recurrent ovarian cancer. We report a novel clinical strategy using PPF: a multimodal, PET and optical, folate receptor (FR)-targeted agent for ovarian cancer imaging. The capabilities of PPF were evaluated in primary human ovarian cancer cells, in vivo xenografts derived from primary cells and ex vivo patient omemtum, as the heterogeneity and phenotype displayed by patients is retained. Primary cells uptake PPF in a FR-dependent manner demonstrating approximately a 5- ...
The cell-membrane folate receptor is a potential molecular tar-get for tumor-selective drug delivery...
Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffic...
A new transplantable ovarian tumor model is presented using a novel folate receptor (FR) positive, m...
A new transplantable ovarian tumor model is presented using a novel folate receptor (FR) positive, m...
Ovarian cancer is the seventh most common cancer in women worldwide, accounting for more deaths than...
Complete resection of tumor lesions in advanced stage ovarian cancer patients is of utmost importanc...
International audienceDespite conventional treatment combining complete macroscopic cytoreductive su...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
Complete resection of tumor lesions in advanced stage ovarian cancer patients is of utmost importanc...
In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. ...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
The cell-membrane folate receptor is a potential molecular tar-get for tumor-selective drug delivery...
Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffic...
A new transplantable ovarian tumor model is presented using a novel folate receptor (FR) positive, m...
A new transplantable ovarian tumor model is presented using a novel folate receptor (FR) positive, m...
Ovarian cancer is the seventh most common cancer in women worldwide, accounting for more deaths than...
Complete resection of tumor lesions in advanced stage ovarian cancer patients is of utmost importanc...
International audienceDespite conventional treatment combining complete macroscopic cytoreductive su...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
Complete resection of tumor lesions in advanced stage ovarian cancer patients is of utmost importanc...
In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. ...
The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluoresce...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
The cell-membrane folate receptor is a potential molecular tar-get for tumor-selective drug delivery...
Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffic...